{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:34:25Z","timestamp":1787236465281,"version":"build-2736575974"},"reference-count":38,"publisher":"Walter de Gruyter GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2026-0870_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Antiphospholipid antibodies (aPL) are essential biomarkers for classification, diagnosis, and risk stratification of antiphospholipid syndrome (APS). Although automated analytical platforms, such as chemiluminescent immunoassay (CLIA), and particle-based multi-analyte technology (PMAT), are increasingly implemented in routine laboratories, uncertainty remains regarding their diagnostic performance and interpretation of quantitative antibody results. We compared ELISA, CLIA, and PMAT for aPL detection and evaluated clinical utility of interval-specific likelihood ratios (LRs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-0870_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective single-center diagnostic accuracy study, 351 patients with APS (238 thrombotic and 113 obstetric APS) and 197 controls were included. IgG and IgM anticardiolipin (aCL) and anti-\u03b22-glycoprotein I (a\u03b22GPI) antibodies were measured using ELISA, CLIA, and PMAT. Analytical agreement was assessed by correlation analysis, and diagnostic performance by ROC analysis. Interval-specific LRs were calculated using predefined specificity thresholds (90\u202f%, 95\u202f%, and\u00a0\u226599\u202f%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-0870_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Strong correlations were observed among all analytical platforms (p&lt;0.001), with the highest agreement found between CLIA and PMAT. Automated platforms showed higher positivity rates than ELISA, particularly for IgM isotypes. PMAT achieved the highest diagnostic accuracy in thrombotic APS for IgG aCL (0.810), IgG a\u03b22GPI (0.816), and IgM a\u03b22GPI (0.848). Increasing antibody concentrations were associated with progressively higher interval-specific LRs, especially at specificity thresholds\u00a0\u226599\u202f%. Diagnostic performance was lower in obstetric\u00a0APS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2026-0870_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Automated platforms, including PMAT represent analytically robust and clinically reliable methodologies for aPL testing, and represent valid alternatives to conventional ELISA assays. Interval-specific LR interpretation provides clinically relevant probabilistic information beyond dichotomous cut-offs, and may improve laboratory-based risk stratification in APS across analytical platforms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2026-0870","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:35:20Z","timestamp":1787232920000},"source":"Crossref","is-referenced-by-count":0,"title":["Interval-specific likelihood ratios improve interpretation of antiphospholipid antibody testing across different analytical platforms"],"prefix":"10.1515","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2315-8671","authenticated-orcid":false,"given":"Juan","family":"Irure-Ventura","sequence":"first","affiliation":[{"name":"Immunology Department , University Hospital Marqu\u00e9s de Valdecilla , Santander , Spain"},{"name":"Immunopathology Group, Marqu\u00e9s de Valdecilla University Hospital-IDIVAL , Santander , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"G\u00e1lvez-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Immunopathology Group, Marqu\u00e9s de Valdecilla University Hospital-IDIVAL , Santander , Spain"},{"name":"Rheumatology Department , University Hospital Marqu\u00e9s de Valdecilla , Santander , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Mota-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Immunology Department , University Hospital Marqu\u00e9s de Valdecilla , Santander , Spain"},{"name":"Immunopathology Group, Marqu\u00e9s de Valdecilla University Hospital-IDIVAL , Santander , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6200-8620","authenticated-orcid":false,"given":"Rodrigo","family":"Cantera-Estefan\u00eda","sequence":"additional","affiliation":[{"name":"Hematology Department , Hospital Universitario de Navarra , Pamplona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8353-6211","authenticated-orcid":false,"given":"Alejandra","family":"Comins-Boo","sequence":"additional","affiliation":[{"name":"Immunology Department , University Hospital Marqu\u00e9s de Valdecilla , Santander , Spain"},{"name":"Immunopathology Group, Marqu\u00e9s de Valdecilla University Hospital-IDIVAL , Santander , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Isabel","family":"Merino-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Gynecology and Obstetrics Department , University Hospital Marqu\u00e9s de Valdecilla , Santander , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Hern\u00e1ndez-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Immunopathology Group, Marqu\u00e9s de Valdecilla University Hospital-IDIVAL , Santander , Spain"},{"name":"Internal Medicine Department , University Hospital Marqu\u00e9s de Valdecilla , Santander , Spain"},{"name":"Molecular Biology Department , University of Cantabria , Santander , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor Manuel","family":"Mart\u00ednez-Taboada","sequence":"additional","affiliation":[{"name":"Immunopathology Group, Marqu\u00e9s de Valdecilla University Hospital-IDIVAL , Santander , Spain"},{"name":"Rheumatology Department , University Hospital Marqu\u00e9s de Valdecilla , Santander , Spain"},{"name":"Molecular Biology Department , University of Cantabria , Santander , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"L\u00f3pez-Hoyos","sequence":"additional","affiliation":[{"name":"Immunology Department , University Hospital Marqu\u00e9s de Valdecilla , Santander , Spain"},{"name":"Immunopathology Group, Marqu\u00e9s de Valdecilla University Hospital-IDIVAL , Santander , Spain"},{"name":"Molecular Biology Department , University of Cantabria , Santander , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"2026082013351733983_j_cclm-2026-0870_ref_001","doi-asserted-by":"crossref","unstructured":"Cervera, R. Antiphospholipid syndrome. Thromb Res 2017;151:S43\u20137. https:\/\/doi.org\/10.1016\/s0049-3848(17)30066-x.","DOI":"10.1016\/S0049-3848(17)30066-X"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_002","doi-asserted-by":"crossref","unstructured":"Gaspar, P, Sciascia, S, Tektonidou, MG. Epidemiology of antiphospholipid syndrome: macro- and microvascular manifestations. Rheumatology 2024;63:SI24\u201336. https:\/\/doi.org\/10.1093\/rheumatology\/kead571.","DOI":"10.1093\/rheumatology\/kead571"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_003","doi-asserted-by":"crossref","unstructured":"Devreese, KMJ, Bertolaccini, ML, Branch, DW, de Laat, B, Erkan, D, Favaloro, EJ, et al.. An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC subcommittee on lupus anticoagulant\/antiphospholipid antibodies. J\u00a0Thromb Haemost 2025;23:731\u201344. https:\/\/doi.org\/10.1016\/j.jtha.2024.10.022.","DOI":"10.1016\/j.jtha.2024.10.022"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_004","doi-asserted-by":"crossref","unstructured":"Knight, JS, Kanthi, Y. Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome. Semin Immunopathol 2022;44:347\u201362. https:\/\/doi.org\/10.1007\/s00281-022-00916-w.","DOI":"10.1007\/s00281-022-00916-w"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_005","doi-asserted-by":"crossref","unstructured":"Barbhaiya, M, Zuily, S, Naden, R, Hendry, A, Manneville, F, Amigo, MC, et al.. The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria. Arthritis Rheumatol 2023;75:1687\u2013702.","DOI":"10.1002\/art.42624"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_006","doi-asserted-by":"crossref","unstructured":"Lakos, G, Favaloro, EJ, Harris, EN, Meroni, PL, Tincani, A, Wong, RC, et al.. International consensus guidelines on anticardiolipin and anti-\u03b22-glycoprotein I testing: report from the 13th international congress on antiphospholipid antibodies. Arthritis Rheum 2012;64:1\u201310. https:\/\/doi.org\/10.1002\/art.33349.","DOI":"10.1002\/art.33349"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_007","doi-asserted-by":"crossref","unstructured":"Thirunavukarasu, C, Pasalic, L, Favaloro, EJ. A contemporary analysis of solid-phase antiphospholipid antibody testing: implications for classification or diagnosis of antiphospholipid syndrome. Pathology 2026;58:76\u201384. https:\/\/doi.org\/10.1016\/j.pathol.2025.07.003.","DOI":"10.1016\/j.pathol.2025.07.003"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_008","doi-asserted-by":"crossref","unstructured":"Pengo, V, Biasiolo, A, Bison, E, Chantarangkul, V, Tripodi, A, Italian Federation of Anticoagulation Clinics (FCSA). Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-Glycoprotein I activity. Thromb Res 2007;120:127\u201333.","DOI":"10.1016\/j.thromres.2006.07.014"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_009","doi-asserted-by":"crossref","unstructured":"Chayoua, W, Kelchtermans, H, Moore, GW, Gris, JC, Musial, J, Wahl, D, et al.. Detection of anti-cardiolipin and anti-\u03b22-glycoprotein I antibodies differs between platforms without influence on association with clinical symptoms. Thromb Haemost 2019;119:797\u2013806. https:\/\/doi.org\/10.1055\/s-0039-1679901.","DOI":"10.1055\/s-0039-1679901"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_010","doi-asserted-by":"crossref","unstructured":"Devreese, KM, Poncet, A, Lindhoff-Last, E, Musial, J, de Moerloose, P, Fontana, P. A multicenter study to assess the reproducibility of antiphospholipid antibody results produced by an automated system. J\u00a0Thromb Haemost 2017;15:91\u20135. https:\/\/doi.org\/10.1111\/jth.13560.","DOI":"10.1111\/jth.13560"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_011","doi-asserted-by":"crossref","unstructured":"Sciascia, S, Radin, M, Ramirez, C, Seaman, A, Bentow, C, Casas, S, et al.. Evaluation of novel assays for the detection of autoantibodies in antiphospholipid syndrome. Autoimmun Rev 2020;19:102641. https:\/\/doi.org\/10.1016\/j.autrev.2020.102641.","DOI":"10.1016\/j.autrev.2020.102641"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_012","doi-asserted-by":"crossref","unstructured":"Favaloro, EJ, Wong, RCW. Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays. Clin Chem Lab Med 2011;49:447\u201361. https:\/\/doi.org\/10.1515\/cclm.2011.064.","DOI":"10.1515\/CCLM.2011.064"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_013","doi-asserted-by":"crossref","unstructured":"Miyakis, S, Lockshin, MD, Atsumi, T, Branch, DW, Brey, RL, Cervera, R, et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J\u00a0Thromb Haemost 2006;4:295\u2013306. https:\/\/doi.org\/10.1111\/j.1538-7836.2006.01753.x.","DOI":"10.1111\/j.1538-7836.2006.01753.x"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_014","doi-asserted-by":"crossref","unstructured":"Cantera Estefan\u00eda, R, G\u00e1lvez S\u00e1nchez, R, Abando Casuso, M, Flores Garc\u00eda, JA, Garc\u00eda Ruiz, R, Gorostidi \u00c1lvarez, I, et al.. Assessment of 2023 ACR\/EULAR antiphospholipid syndrome classification criteria in a Spanish cohort. Clin Chem Lab Med 2025;63:2272\u201381. https:\/\/doi.org\/10.1515\/cclm-2025-0508.","DOI":"10.1515\/cclm-2025-0508"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_015","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Taboada, VM, G\u00f3mez, AM, Del Barrio-Longarela, S, Merino, A, Comins-Boo, A, L\u00f3pez-Hoyos, M, et al.. Impact of the 2023 ACR\/EULAR classification criteria in women with primary antiphospholipid syndrome during pregnancy. Diagnostics 2024;14:2162. https:\/\/doi.org\/10.3390\/diagnostics14192162.","DOI":"10.3390\/diagnostics14192162"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_016","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Taboada, VM, G\u00f3mez, AM, Merino, A, L\u00f3pez-Hoyos, M, Del Barrio-Longarela, S, Comins-Boo, A, et al.. Are the new 2023 ACR\/EULAR classification criteria suitable for advancing the knowledge of obstetric antiphospholipid syndrome? Autoimmun Rev 2024;23:103592. https:\/\/doi.org\/10.1016\/j.autrev.2024.103592.","DOI":"10.1016\/j.autrev.2024.103592"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_017","doi-asserted-by":"crossref","unstructured":"Damoiseaux, J. Autoantibodies in the criteria of autoimmune diseases: is it sufficient to know that the test is positive? J\u00a0Transl Autoimmun 2022;5:100144. https:\/\/doi.org\/10.1016\/j.jtauto.2022.100144.","DOI":"10.1016\/j.jtauto.2022.100144"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_018","doi-asserted-by":"crossref","unstructured":"Bossuyt, X. Clinical performance characteristics of a laboratory test. A practical approach in the autoimmune laboratory. Autoimmun Rev 2009;8:543\u20138. https:\/\/doi.org\/10.1016\/j.autrev.2009.01.013.","DOI":"10.1016\/j.autrev.2009.01.013"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_019","doi-asserted-by":"crossref","unstructured":"Fierz, W, Bossuyt, X. Likelihood ratio approach and clinical interpretation of laboratory tests. Front Immunol 2021;12:655262. https:\/\/doi.org\/10.3389\/fimmu.2021.655262.","DOI":"10.3389\/fimmu.2021.655262"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_020","doi-asserted-by":"crossref","unstructured":"Bossuyt, X, Van Hoovels, L. Reporting likelihood ratio in autoimmune serology: just a theory or feasible in practice? Clin Chem 2024;70:482\u20135. https:\/\/doi.org\/10.1093\/clinchem\/hvad222.","DOI":"10.1093\/clinchem\/hvad222"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_021","doi-asserted-by":"crossref","unstructured":"Deane, KD, Van Hoovels, L, Joy, VE, Olschowka, N, Bossuyt, X. From autoantibody test results to decision making: incorporating likelihood ratios within medical practice. Autoimmun Rev 2024;23:103537. https:\/\/doi.org\/10.1016\/j.autrev.2024.103537.","DOI":"10.1016\/j.autrev.2024.103537"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_022","doi-asserted-by":"crossref","unstructured":"Meroni, PL, Borghi, MO, Grossi, C, Chighizola, CB, Durigutto, P, Tedesco, F. Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases? Nat Rev Rheumatol 2018;14:433\u201340. https:\/\/doi.org\/10.1038\/s41584-018-0032-6.","DOI":"10.1038\/s41584-018-0032-6"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_023","doi-asserted-by":"crossref","unstructured":"Cinquanta, L, Fontana, DE, Bizzaro, N. Chemiluminescent immunoassay technology: what does it change in autoantibody detection? Autoimmun Highlights 2017;8:9. https:\/\/doi.org\/10.1007\/s13317-017-0097-2.","DOI":"10.1007\/s13317-017-0097-2"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_024","doi-asserted-by":"crossref","unstructured":"Lai, EEN, Lim, CXQ, Lau, JPJ, Chee, YL, Chan, SSW, Teo, WZY, et al.. Diagnosis of antiphospholipid syndrome by chemiluminescent or enzyme-linked immunosorbent assay: a comparison study and comprehensive literature review. Clin Appl Thromb Hemost 2025;31:10760296251325527. https:\/\/doi.org\/10.1177\/10760296251325527.","DOI":"10.1177\/10760296251325527"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_025","doi-asserted-by":"crossref","unstructured":"Saadalla, A, Novis, CL, Banerjee, D, Martins, T, Holloway, B, Ann Aure, M, et al.. Comparative assessment of the diagnostic performances of particle-based multianalyte technology and commercial ELISA for antiphospholipid autoantibody testing. Clin Chim Acta 2024;562:119849. https:\/\/doi.org\/10.1016\/j.cca.2024.119849.","DOI":"10.1016\/j.cca.2024.119849"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_026","doi-asserted-by":"crossref","unstructured":"Ricchiuti, V, Obney, J, Holloway, B, Aure, MA, Shapiro, M, Bentow, C, et al.. Comparison of five assays for the detection of anti-dsDNA antibodies and their correlation with complement consumption. Diagnostics 2025;15:2430. https:\/\/doi.org\/10.3390\/diagnostics15192430.","DOI":"10.3390\/diagnostics15192430"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_027","doi-asserted-by":"crossref","unstructured":"Radin, M, Cecchi, I, Foddai, SG, Rubini, E, Barinotti, A, Ramirez, C, et al.. Validation of the particle-based multi-analyte technology for detection of anti-phosphatidylserine\/prothrombin antibodies. Biomedicines 2020;8:622. https:\/\/doi.org\/10.3390\/biomedicines8120622.","DOI":"10.3390\/biomedicines8120622"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_028","doi-asserted-by":"crossref","unstructured":"Jiang, H, Yang, Y, Tang, Z, Pan, H, Liu, H, Cheng, X, et al.. Detection of moderate to high antiphospholipid antibodies by chemiluminescence meets 2023 APS classification criteria. Sci Rep 2025;15:19083. https:\/\/doi.org\/10.1038\/s41598-025-04097-y.","DOI":"10.1038\/s41598-025-04097-y"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_029","doi-asserted-by":"crossref","unstructured":"O\u010dkov\u00e1, M, Anunciaci\u00f3n-Llunell, A, Andrada, C, Esteve-Valverde, E, Mir\u00f3-Mur, F, Alijotas-Reig, J. IgM antiphospholipid antibodies in antiphospholipid syndrome: prevalence, clinical associations, and diagnostic implications-a scoping review. J\u00a0Clin Med 2025;14:7164. https:\/\/doi.org\/10.3390\/jcm14207164.","DOI":"10.3390\/jcm14207164"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_030","doi-asserted-by":"crossref","unstructured":"Gkrouzman, E, Willis, R, Andrade, D, Tektonidou, MG, Pengo, V, Ruiz-Irastorza, G, et al.. Associations among antiphospholipid antibody types, isotypes, and titers: an antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) study. Lab Invest 2023;103:100147. https:\/\/doi.org\/10.1016\/j.labinv.2023.100147.","DOI":"10.1016\/j.labinv.2023.100147"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_031","doi-asserted-by":"crossref","unstructured":"Anunciaci\u00f3n-Llunell, A, Mu\u00f1oz, C, Roggenbuck, D, Frasca, S, Pardos-Gea, J, Esteve-Valverde, E, et al.. Differences in antiphospholipid antibody profile between patients with obstetric and thrombotic antiphospholipid syndrome. Int J Mol Sci 2022;23:12819. https:\/\/doi.org\/10.3390\/ijms232112819.","DOI":"10.3390\/ijms232112819"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_032","doi-asserted-by":"crossref","unstructured":"Irure-Ventura, J, D\u00edaz-Toledo, M, Palazuelos-Cay\u00f3n, N, L\u00f3pez-Hoyos, M. Impact of likelihood ratios of rheumatoid factor and anti-cyclic citrullinated peptide antibody in clinical diagnosis of rheumatoid arthritis by two available platforms. Diagnostics 2025;15:135. https:\/\/doi.org\/10.3390\/diagnostics15020135.","DOI":"10.3390\/diagnostics15020135"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_033","doi-asserted-by":"crossref","unstructured":"Van Hoovels, L, Vander Cruyssen, B, Sieghart, D, Bonroy, C, Nagy, E, Pullerits, R, et al.. Multicentre study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein\/peptide antibodies test results. RMD Open 2022;8:e002099. https:\/\/doi.org\/10.1136\/rmdopen-2021-002099.","DOI":"10.1136\/rmdopen-2021-002099"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_034","doi-asserted-by":"crossref","unstructured":"Vandebeek, D, Lodewijckx, E, Van Hoovels, L, Verschueren, P, Bossuyt, X. Integrating pretest probability for rheumatoid arthritis with likelihood ratios of RF and ACPA to improve clinical utility of rheumatoid arthritis autoantibody testing. Clin Chim Acta 2025;564:119928. https:\/\/doi.org\/10.1016\/j.cca.2024.119928.","DOI":"10.1016\/j.cca.2024.119928"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_035","doi-asserted-by":"crossref","unstructured":"Bossuyt, X, Rasmussen, N, van Paassen, P, Hellmich, B, Baslund, B, Vermeersch, P, et al.. A multicentre study to improve clinical interpretation of proteinase-3 and myeloperoxidase anti-neutrophil cytoplasmic antibodies. Rheumatology 2017;56:1533\u201341. https:\/\/doi.org\/10.1093\/rheumatology\/kex266.","DOI":"10.1093\/rheumatology\/kex170"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_036","doi-asserted-by":"crossref","unstructured":"Vermeersch, P, Coenen, D, Geboes, K, Mari\u00ebn, G, Hiele, M, Bossuyt, X. Use of likelihood ratios improves clinical interpretation of IgA anti-tTG antibody testing for celiac disease. Clin Chim Acta 2010;411:13\u20137. https:\/\/doi.org\/10.1016\/j.cca.2009.09.030.","DOI":"10.1016\/j.cca.2009.09.030"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_037","doi-asserted-by":"crossref","unstructured":"Bossuyt, X, Claessens, J, Belmondo, T, De Langhe, E, Westhovens, R, Poesen, K, et al.. Harmonization of clinical interpretation of antinuclear antibody test results by solid phase assay and by indirect immunofluorescence through likelihood ratios. Autoimmun Rev 2019;18:102386. https:\/\/doi.org\/10.1016\/j.autrev.2019.102386.","DOI":"10.1016\/j.autrev.2019.102386"},{"key":"2026082013351733983_j_cclm-2026-0870_ref_038","doi-asserted-by":"crossref","unstructured":"Van Hoovels, L, Piantoni, S, Bailleul, E, Schouwers, S, Radin, M, Infantino, M, et al.. Multicenter study to improve clinical interpretation of anticardiolipin and anti-\u03b22-glycoprotein I antibody test results for diagnosis of antiphospholipid syndrome. J\u00a0Thromb Haemost 2025;23:2584\u201397. https:\/\/doi.org\/10.1016\/j.jtha.2025.05.008.","DOI":"10.1016\/j.jtha.2025.05.008"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0870\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0870\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:35:52Z","timestamp":1787232952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0870\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":38,"alternative-id":["10.1515\/cclm-2026-0870"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2026-0870","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]}}}